Evolent Health (NYSE:EVH) Posts Earnings Results, Misses Expectations By $0.35 EPS

Evolent Health (NYSE:EVH) announced its quarterly earnings data on Thursday. The technology company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35), Zacks reports. The firm had revenue of $646.54 million during the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. Evolent Health updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Evolent Health Trading Down 2.5 %

Shares of NYSE EVH opened at $10.44 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock’s 50 day moving average price is $10.75 and its two-hundred day moving average price is $18.85. Evolent Health has a 52-week low of $9.45 and a 52-week high of $35.00. The stock has a market capitalization of $1.22 billion, a P/E ratio of -12.73 and a beta of 1.45.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Barclays decreased their target price on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Stephens reduced their target price on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. JMP Securities restated a “market outperform” rating and issued a $12.00 price objective on shares of Evolent Health in a research report on Friday, February 14th. Citigroup lowered their price objective on Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, Piper Sandler restated an “overweight” rating and issued a $16.00 price target (down from $17.00) on shares of Evolent Health in a research note on Friday. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $17.79.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.